Reduced plasma cell and DC infiltration may indicate weakened antibody-mediated anti-tumor effects, TLS deficiency, and inadequate immune surveillance, potentially with increased Bregs or M2-type TAMs, leading to insufficient CD8+ T cell activation, further exacerbating immune escape, and diminished immunotherapy response. The gene discussed is CD8A; the disease is neoplasm.